Key result
Multiple antiplatelet agents compared to a single agent will be assessed for preventing early recurrence of stroke or TIA in this Cochrane Review protocol.
Why the study?
Do multiple antiplatelet agents prevent early recurrence of stroke or TIA in patients after an ischaemic stroke or TIA compared to a single agent?
Do multiple antiplatelet agents prevent early recurrence of stroke or TIA in patients after an ischaemic stroke or TIA compared to a single agent?
This is a protocol for a Cochrane Review to evaluate the efficacy of multiple versus single antiplatelet agents for preventing early recurrence after ischemic stroke or TIA.
Uncertainty persists on multiple vs single antiplatelet agents for early post-TIA/stroke prevention; this protocol extends systematic evaluation of the question.
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: The objective of this review is to assess the efficacy of multiple antiplatelet agents versus a single agent given after an ischaemic stroke or TIA in the prevention of early recurrence of stroke or TIA.
No takes yet. Share an insight, caveat, or question.
Kamal et al. (2012) studied this question. Multiple antiplatelet agents compared to a single agent will be assessed for preventing early recurrence of stroke or TIA in this Cochrane Review protocol.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: